Cargando…

Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy

Lymphatic metastasis is a major determinant of the outcome of resected pancreatic cancer. Gemcitabine-based adjuvant chemotherapy can improve the outcome of resected pancreatic cancer. However, the efficacy of gemcitabine against pancreatic cancer stratified by nodal involvement is unclear. In this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Chen, Cheng, He, Jin, Kaizhou, Fan, Zhiyao, Gong, Yitao, Qian, Yunzhen, Deng, Shengming, Huang, Qiuyi, Ni, Quanxing, Yu, Xianjun, Luo, Guopei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153189/ https://www.ncbi.nlm.nih.gov/pubmed/32268796 http://dx.doi.org/10.1177/1073274820915947

Ejemplares similares

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2020)

Lewis antigen-negative pancreatic cancer: An aggressive subgroup
por: Liu, Chen, et al.
Publicado: (2020)

Absolute Counts of Peripheral Lymphocyte Subsets Correlate with the Progression-Free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumour Patients
por: Gong, Yitao, et al.
Publicado: (2020)

High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma
por: Gong, Yitao, et al.
Publicado: (2021)

Prognosis of distal pancreatic cancers controlled by stage
por: Luo, Guopei, et al.
Publicado: (2020)

Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms
por: Deng, Shengming, et al.
Publicado: (2021)

The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer
por: Fan, Zhiyao, et al.
Publicado: (2019)

AJCC 7th edition staging classification is more applicable than AJCC 8th edition staging classification for invasive IPMN
por: Fan, Zhiyao, et al.
Publicado: (2019)

Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreas
por: Deng, Shengming, et al.
Publicado: (2020)

The role of necroptosis in cancer biology and therapy
por: Gong, Yitao, et al.
Publicado: (2019)

Hexokinase 2 dimerization and interaction with voltage‐dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer
por: Fan, Kun, et al.
Publicado: (2019)

Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients
por: Cheng, He, et al.
Publicado: (2020)

The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer
por: Guo, Meng, et al.
Publicado: (2016)

Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
por: Zhang, Yiyin, et al.
Publicado: (2018)

Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer
por: Jin, Kaizhou, et al.
Publicado: (2015)

Glutamine deprivation induces ferroptosis in pancreatic cancer cells: Glutamine deprivation induces pancreatic cancer ferroptosis
por: Xiao, Zhiwen, et al.
Publicado: (2023)

Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2022)

Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
por: Li, Haorui, et al.
Publicado: (2023)

Glutamine is a substrate for glycosylation and CA19-9 biosynthesis through hexosamine biosynthetic pathway in pancreatic cancer
por: Liu, Chen, et al.
Publicado: (2023)

Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy
por: Matsui, Hiroto, et al.
Publicado: (2017)

hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
por: Wang, Wei, et al.
Publicado: (2023)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
por: Heinrich, Stefan, et al.
Publicado: (2011)

Molecular Mechanism Underlying Lymphatic Metastasis in Pancreatic Cancer
por: Xiao, Zhiwen, et al.
Publicado: (2014)

Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer?
por: Liu, Chen, et al.
Publicado: (2016)

Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going
por: Liang, Chen, et al.
Publicado: (2017)

Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis
por: Zhang, Yiyin, et al.
Publicado: (2019)

Carbohydrate antigen 125 supplements carbohydrate antigen 19-9 for the prediction of invasive intraductal papillary mucinous neoplasms of the pancreas
por: Qian, Yunzhen, et al.
Publicado: (2022)

Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resection
por: Xing, Jiazhang, et al.
Publicado: (2021)

FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1
por: Hu, Qiangsheng, et al.
Publicado: (2017)

Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma
por: Habermehl, Daniel, et al.
Publicado: (2015)

Somatic Genetic Variation in Solid Pseudopapillary Tumor of the Pancreas by Whole Exome Sequencing
por: Guo, Meng, et al.
Publicado: (2017)

Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
por: Park, Se Jun, et al.
Publicado: (2019)

Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy
por: Aoyama, Toru, et al.
Publicado: (2017)

Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2022)

TGF-β1-induced RAP2 regulates invasion in pancreatic cancer: RAP2 regulates invasion in pancreatic cancer
por: Jin, Kaizhou, et al.
Publicado: (2022)

Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
por: Blackstock, A W, et al.
Publicado: (2006)

Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone
por: Chen, Hua, et al.
Publicado: (2018)

Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
por: Chen, Emerson Y., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f0k45kj1nfs6h10lla7m9fqlnu